Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun(Western University), Walter Reinisch(Medical University of Vienna), Honghui Zhou(Janssen (United States)), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Freddy Cornillie(MSD (Switzerland)), Hugh M. Davis(South College), Zhenhua Xu(Hebei Medical University), Paul Rutgeerts(KU Leuven), Jewel Johanns(Johnson & Johnson (United States))
Cited by 339
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k